The promise of personalized medicine depends on discovering critical insights into tumor biology that can uncover new therapeutic targets and biomarker signatures that inform care. Structural variants (SVs) are a hallmark of cancer, yet current cytogenetic and molecular methods fail to detect all classes and sizes of SVs, missing a significant amount of information critical to understanding cancer biology.1-16 Studies have shown that a significant portion of SVs detected by optical genome mapping (OGM) are being missed by traditional cytogenetic and next-generation sequencing (NGS) approaches.2,16,17
Leverage OGM to maximize SV detection, so you can build comprehensive genomic profiles of hematological malignancies and solid tumors, deepening your understanding of cancer biology and unlocking new precision medicine possibilities.
Leverage OGM’s unbiased, genome-wide, and high-resolution capabilities to detect all classes of SVs, maximize pathogenic findings and increase the number of informed cases in hematological malignancies and solid tumor samples.
Unveil new meaningful events with OGM, from single SVs to complex events such as chromothripsis, or even genome-wide signatures such as homologous recombination deficiency.
Combine findings from OGM and NGS to uncover more pathogenic insights and generate comprehensive genomic profiles of tumor samples that deepen the understanding of underlying pathology.
Detect chromosomal aberrations commonly found with traditional cytogenetics while revealing incremental pathogenic findings using a single, easy-to-implement OGM workflow.Learn More
Use OGM to uncover meaningful SVs in solid tumor genomes that can’t be seen with NGS approaches.Learn More
Use OGM and Bionano software solutions to characterize HRD in tumor samples.Learn More
Check out expert presentations on the utility of OGM for evaluating hematological malignancies.Watch Videos
Explore the growing evidence for OGM performance in heme in this downloadable publication summary.Read More
|Cytogenetics in the management of Multiple Myeloma: the guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)||
October 24, 2023
|Agnès Daudignon, Wendy Cuccuini, Claire Bracquemart, et al.|
|Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood ETV6::RUNX1+ and High Hyperdiploid Acute Lymphoblastic Leukemia||
August 1, 2023
|Danielle Brandes, Layal Yasin, Karin Nebral, et al.|
|Assembly of 43 diverse human Y chromosomes reveals extensive complexity and variation||
June 12, 2023
|Pille Hallast, Peter Ebert, Mark Loftus, et al.|